IV Ketamine Vs. in Esketamine for MDD TRD

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

March 20, 2026

Study Completion Date

October 20, 2026

Conditions
Treatment Resistant Depression
Interventions
DRUG

Low dose IV Ketamine vs. IN Esketamine

For IV ketamine treatment, ketamine is administered at 0.5mg/kg over 40 minutes. For IN esketamine treatment, esketamine is administered as a nasal spray, two sprays per nostril (56mg total) for the first treatment and three sprays per nostril (84mg) for the rest of the acute series. All treatments are administered at the academic center under the supervision of a mental health care professional. Patients are asked to come fasting at least two hours prior to treatment and to remain resting in the treatment room throughout the dosing session. Throughout each dosing session, blood pressure, oxygen levels, and onset, duration and severity of common side effects are recorded by nursing staff and/or physicians. Patients are discharged after a minimum of 30 minutes post administration, provided that the vital signs return to baseline and that the patient is calm, alert, and oriented.

Trial Locations (1)

K7L4X3

RECRUITING

Providence Care Hospital, Kingston

All Listed Sponsors
collaborator

Centre for Addiction and Mental Health

OTHER

collaborator

Envision Mind Care

UNKNOWN

collaborator

Sunnybrook Health Sciences Centre

OTHER

collaborator

Djavad Mowafaghian Centre for Brain Health

UNKNOWN

lead

Gustavo Vazquez

OTHER

NCT06488586 - IV Ketamine Vs. in Esketamine for MDD TRD | Biotech Hunter | Biotech Hunter